These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 23544718)

  • 21. A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.
    Fredrikson S; McLeod E; Henry N; Pitcher A; Lowin J; Cuche M; Fajutrao L; Perard R; Bates D; Chan A
    J Med Econ; 2013; 16(6):756-62. PubMed ID: 23556422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study.
    Tan H; Yu J; Tabby D; Devries A; Singer J
    Mult Scler; 2010 Aug; 16(8):956-63. PubMed ID: 20595246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications for multiple sclerosis in the era of the Affordable Care Act: the shifting managed care landscape.
    Mathis AS; Owens GM
    Am J Manag Care; 2014 Dec; 20(11 Suppl):S242-53. PubMed ID: 25734889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managed care aspects of managing multiple sclerosis.
    Mathis AS
    Am J Manag Care; 2013 Feb; 19(2 Suppl):S28-34. PubMed ID: 23544718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies.
    Owens GM; Olvey EL; Skrepnek GH; Pill MW
    J Manag Care Pharm; 2013; 19(1 Suppl A):S41-53. PubMed ID: 23383732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managed approaches to multiple sclerosis in special populations.
    Sperandeo K; Nogrady L; Moreo K; Prostko CR
    J Manag Care Pharm; 2011; 17(9 Suppl C):S1-19; quiz S20-1. PubMed ID: 22107156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managed care aspects of managing multiple sclerosis.
    Owens GM
    Am J Manag Care; 2013 Nov; 19(16 Suppl):s307-12. PubMed ID: 24494620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.
    Phillips CJ
    CNS Drugs; 2004; 18(9):561-74. PubMed ID: 15222773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.